Chemoprevention of cancer - Focusing on clinical trials

Japanese Journal of Clinical Oncology

Volumn 33, Issue 9, 2003, Pages 421-442

  Kakizoe, Tadao ^a  

^a NATIONAL CANCER CENTER   (Japan)

Author keywords

Cancer; Chemoprevention; Clinical trial

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BETA CAROTENE; BROPIRIMINE; BUTYRIC ACID; CALCIUM; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; FOLIC ACID; GENISTEIN; GLYCYRRHETINIC ACID; ISOTHIOCYANIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OLTIPRAZ; POLYPHENOL DERIVATIVE; POLYPRENOIC ACID; PRASTERONE; PROTEINASE INHIBITOR; PYRIDOXINE; RETINOIC ACID DERIVATIVE; RETINOID DERIVATIVE; RETINOL; SELENIUM; TAMOXIFEN; TERPENE; UNINDEXED DRUG; VITAMIN D; RETINOIC ACID;

ADOPTIVE IMMUNOTHERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CHEILITIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; DNA REPAIR; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRY SKIN; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; HEAD AND NECK CANCER; HEAD AND NECK TUMOR; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; JAPAN; LIVER CELL CARCINOMA; LUNG CANCER; METHODOLOGY; MUCOSAL DRYNESS; NONHUMAN; ONCOLOGY; POLYAMINE METABOLISM; PROSTATE CANCER; REVIEW; SCAVENGING SYSTEM; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH PERFORATION; ANIMAL; BLADDER TUMOR; BREAST TUMOR; COLORECTAL TUMOR; FEMALE; LUNG TUMOR; MALE; NEOPLASM; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE TUMOR;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; BETA CAROTENE; BREAST NEOPLASMS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COLORECTAL NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; TAMOXIFEN; TRETINOIN; URINARY BLADDER NEOPLASMS;

EID: 0642341485     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg090     Document Type: Review

References (125)

1. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976;36:2689-702.
2. Greenwald P, Kelloff GJ. The role of chemoprevention in cancer control. In: Stewart BW, McGregor D, Kleihues P, editors. Principles of Chemoprevention. IARC Scientific Publication No. 139. Lyon: IARC 1996;13-22.
3. National Cancer Institute. Highlights of NCI's Prevention and Control Programs. http://cis.nci.nih.gov/fact/4.5.htm.
4. Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet RA, Greenwald P, et al. Mechanistic considerations in the evaluation of chemopreventive data. In: Stewart BW, McGregor D, Kleihues P, editors. Principles of Chemoprevention. IARC Scientific Publication No. 139. Lyon: IARC 1996;203-19.
5. Pence BC. Role of calcium in colon cancer prevention: Experimental and clinical studies. Mutat Res 1993;290:87-95.
6. Mirvish SS. Effects of vitamins C and E on N-nitroso compound formation, carcinogenesis and cancer. Cancer 1986;58:1842-50.
7. Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ. Chemopreventive effects of the aromatase inhibitors vorozole (R83842) and 4-hydroxyandrostenedione in the methylnitrosourea induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 1994;15:2775-80.
8. 1 hepatocarcinogenesis in the rat. Cancer Res 1987;47:5218-23.
9. Roebuck BD, Lie Y-L, Rogers AE, Groopman JD, Kensler TW. Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): Predictive role for short-term molecular dosimetry. Cancer Res 1991;51:5501-6.
10. Kensler TW, Trush MA, Guyton KZ. Free radicals as targets for cancer chemoprevention: Prospects and problems. In: Steele VE, Stoner GD, Boone CW, Kelloff GJ, editors. Cellular and Molecular Targets for Chemoprevention. Boca Raton, FL: CRC Press 1992;173-91.
11. Zenser TV, Davis BB. Arachidomic acid metabolism. In: Steele VE, Stoner GD, Boone CW, Kelloff GJ, editors. Cellular and Molecular Targets for Chemoprevention. Boca Raton, FL: CRC Press 1992;225-43.
12. Powis G, Workman P. Signalling targets for the development of cancer drugs. Anticancer Drug Des 1994;9:554-68.
13. Glick AB, McCune BK, Abdulkarem N, Flanders KC, Lumadue JA, Smith JM, et al. Complex regulation of TGFB expression by retinoic acid in the vitamin A-deficient rat. Development 1991;111:1081-6.
14. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 1988;48:759-74.
15. De Flora S, Ramel C. Mechanism of inhibitors of metagenesis and carcinogenesis. Classification and overview. Mutat Res 1988;202:285-306.
16. Steele VE, Moon RC, Lubet RA, Grubbs CJ, Reddy BS, Wargovich M, et al. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI Chemoprevention Drug Development Program. J Cell Biochem 1994;20:32-54.
17. Murakoshi M, Nishino H, Satomi Y, Takayasu J, Hasegawa T, Tokuda H, et al. Potent preventive action of alpha-carotene against carcinogenesis: spontaneous liver carcinogenesis and promoting stage of lung and skin carcinogenesis in mice are suppressed more effectively by alpha-carotene than by beta-carotene. Cancer Res 1992;52:6583-7.
18. Ito N, Imaida K. Strategy of research for cancer-chemoprevention. Teratog Carcinog Mutagen 1992;12:79-95.
19. Wingo PA, Tong T, Bolder S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30.
20. Manson JE, Tosteson H, Ridker PM, Satterfield S, Hebert P, O'Connor GT, et al. The primary prevention of myocardial infarction. N Engl J Med 1992;326:1406-16.
21. Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: An analysis of 315 cases. J Urol 1982;127:250-4.
22. Kakizoe T, Tobisu K, Tanaka Y, Mizutani T, Teshima S, Kishi K, et al. Development of multiple transitional cell carcinomas in the urinary tract. Jpn J Clin Oncol 1991;21:110-4.
23. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: Clinical implication of multicentric origin. Cancer 1953;6:963-8.
24. Kakizoe T, Matsumoto K, Nishio Y, Ohtani M, Kishi K. Significance of carcinoma in situ and dysplasia in association with bladder cancer. J Urol 1985;133:395-8.
25. Sidransky D, Frost P, Eschenbach AV, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med 1992;326:737-40.
26. Harris AL, Phil D, Neal DE. Bladder cancer - field versus clonal origin. N Engl J Med 1992;326:759-61.
27. Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 1993;342:1087-8.
28. Takahashi T, Habuchi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 1998;58:5835-41.
29. Akaza H, Kurth KH, Hinotsu S, Jewett MAS, Naito K, Okada K, et al. Intravesicle chemotherapy and immunotherapy for superficial tumors: basic mechanism of action and future direction. Urol Oncol 1998;4:121-9.
30. Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Sigman CC. Progress in cancer chemoprevention: Perspectives on agent selection and short-term clinical intervention trials. Cancer Res (Suppl) 1994;54:2015s-24s.
31. Lamm DL, Riggs DR, Shriver JS, Van Gilder PE, Roch JF, DeHaven JI. Megadose vitamins in bladder cancer: A double-blind clinical trial. J Urol 1994;151:21-6.
32. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti, E. Acute promyelocytic leukemia: From genetics to treatment. Blood 1994;83:10-25.
33. Mettlin C, Graham S. Dietary risk factors in human bladder cancer. Am J Epidemiol 1979;110:255-63.
34. Eichholzer M, Stahelin HB, Gey KF, Ludin E, Bernasconi F. Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer 1996;66:145-50.
35. Studer UE, Jenzer S, Biedermann C, Chollet D, Kraft R, von Toggenburg H. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 1995; 28:284-90.
36. Cohen SM, Wittenberg JF, Bryan GT. Effect of avitaminosis A and hypervitaminosis A on urinary bladder carcinogenicity of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. Cancer Res 1976;36:2334-9.
37. Sporn MB, Squire RA, Brown CC, Smith JM, Wenk ML, Springer S. 13-cis-Retinoic acid: Inhibition of bladder carcinogenesis in the rat. Science 1977;195:487-9.
38. Grubbs CJ, Moon RC, Squire RA, Farrow GM, Stinson SF, Goodan DG, et al. 13-cis-Retinoic acid: Inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine. Science 1977;198:743-6.
39. Murasaki G, Miyata Y, Babaya K, Atai M, Fukushima S, Ito N. Inhibitory effect of an aromatic retinoic acid analog on urinary bladder carcinogenesis in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Gann 1980;71:333-40.
40. Moon RC, McCormick DL, Becci PJ, Shealy YF, Frickel F, Paust J. Influence of 15 retinoic acid amides on urinary bladder carcinogenesis in the mouse. Carcinogenesis 1982;3:1469-72.
41. Pollard M, Luckert PH, Sporn MB. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res 1991;51:3610-1.
42. Brown RR, Price JM, Satter EJ, Wear JB. The metabolism of tryptophan in patients with bladder cancer. Acta Int J Cancer 1960;16:299-303.
43. Byar D, Blackard C. Comparisons of placebo, pyridoxine and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 1977; 10:556-61.
44. Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomized phase III study performed by the EORTC GU group. Eur Urol 1975;27:110-6.
45. Schlegel JU. Proposed uses of ascorbic acid in the prevention of bladder carcinoma. Ann N Y Acad Sci 1975;258:432-7.
46. Grubbs CJ, Juliana MM, Eto I, Casebelt T, Whitaber LM, Canfield GJ. Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder tumors. Anticancer Res 1993;13:33-6.
47. Okajima E, Ozono S, Endo T, Majima T, Tsutsumi M, Fukuda T. Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and beta-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4-hydroxybutyl)nitrosamine treatment. Jpn J Cancer Res 1997;88:543-52.
48. Klan R, Knispel HH, Meier T. Acetylsalicylic acid inhibition of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder carcinogenesis in rats. J Cancer Res Clin Onol 1993;119:482-5.
49. Okajima E, Denda A, Ozono S, Takahama M, Aka H, Sasaki Y. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res 1998;588:3028-31.
50. Herzlsouer KJ, Comstock GW, Morris JS. Selenium, lycopene, alphatocopherol, beta-carotene, retinol and subsequent bladder cancer. Cancer Res 1989;49:6144-8.
51. Homma Y, Kakizoe T, Samma S, Oyasu R. Inhibition of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat urinary bladder carcinogenesis by difluoromethylornithine. Cancer Res 1987;47:6167-79.
52. Loprinzi CL, Messing EM, O'Fallon JR, Poon MA, Love RR, Quella SK. Toxicity evaluation of difluoromethylornithine: Doses for chemoprevention trials. Cancer Epidemiol Biomarkers Prev 1996;5:371-4.
53. Sasnowski JT, Lamm DL. Immunotherapy for bladder cancer. In: Rous SN, editor. Urology Annual. East Norwalk, CT. Appleton and Lange 1990;123-5.
54. Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur Urol 1995;27:104-9.
55. Yatani R, Chigusa I, Akazaki K. Geographic pathology of latent prostate carcinoma. Int J Cancer 1982;29:611-6.
56. Lieberman R. Chemoprevention of prostate cancer: Current status and future directions. Cancer Metastasis Rev 2002;21:297-309.
57. Lieberman R. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials. Urology 2001;57:224-9.
58. Lieberman R, Nelson WG, Sakr WA, Myskens FL, Klein EA, Wilding G, et al. Executive summary of the National Cancer Institute Workshop: Highlights and recommendations. Urology 2001;57:4-28.
59. Alberts S, Blute M. Chemoprevention for prostate carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia. Urology 2001;57:188-90.
60. Clark LC, Marshall JR. Randomized controlled chemoprevention trials in populations at very high risk for prostate cancer: Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia. Urology 2001; 57:185-7.
61. Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, et al. Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. Br J Urol 1998;81: 730-4.
62. van der Meijden APM. Practical aspects of clinical trials on chemoprevention of prostate cancer. Eur Urol 1999;35:515-8.
63. Warren JR, Marshall BJ. Unidentified bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;i:1273-5.
64. Forman D. The etiology of gastric cancer. In: O'Neill IK, Chen J, Bartsch H, editors. Relevance to Human Cancer of N-Nitroso Compounds, Tobacco Smoke and Mycotoxins. IARC Scientific Publication No. 105. Lyon: IARC 1991;22-32.
65. Parsonnet J, Friedman GD, Vandersteen DP. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
66. Nomura A, Stemmermann GN, Chyou P-H, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132-6.
67. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
68. Blot WJ, Li J-Y, Taylor PR, Guo W, Dawsey S, Wang G-Q, et al. Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-92.
69. Yamane T, Takahashi T, Kuwata K, Oya K, Inagake M, Kitao Y, et al. Inhibition of N-methyl-N′-nitro-N-nitrosoguanidine-induced carcinogenesis by (-)-epigallocatechin gallate in the rat glandular stomach. Cancer Res 1995;55:2081-4.
70. Nakachi K, Matsuyama S, Miyake S, Suganuma M, Imai K. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Bio Factors 2000; 13:49-54.
71. Anon. Beta carotene and vitamin A halted in lung cancer prevention trial. National Cancer Institute Press Release, January 18, 1996.
72. Tsubono Y, Okubo S, Hayashi M, Kakizoe T, Tsugane S. A randomized controlled trial for chemoprevention of gastric cancer in high-risk Japanese population; study design, feasibility and protocol modification. Jpn J Cancer Res 1997;88:344-9.
73. Sasazuki S, Sasaki S, Tsubono Y, Okubo S, Hayashi M, Kakizoe T, et al. The effect of 5-year vitamin C supplementation on serum pepsinogen level and Helicobacter pylori infection. Cancer Sci 2003;94:378-82.
74. Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996;83:1219-22.
75. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315: 1575-8.
76. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992;15:1013-6.
77. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
78. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomized trial. Lancet 2000;356:802-7.
79. Muto Y, Moriwaki H, Omori M. In vitro binding affinity of novel synthetic polyprenoids (polyprenoic acid) to cellular retinoid binding proteins. Gann 1981;72:974-7.
80. Muto Y, Moriwaki H. Antitumor activities of vitamin A and its derivatives. J Natl Cancer Inst 1984;73:1389-93.
81. Fukutomi Y, Omori M, Muto Y, Ninomiya M, Okuno M, Moriwaki H. Inhibitory effects of acyclic retinoid (polyprenoic acid) and its hydroxyl derivative on cell growth and on secretion of alpha-fetoprotein in human hepatoma-derived cell line (PLC/PRF/5). Jpn J Cancer Res 1990;81: 1281-5.
82. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996;334: 1561-7.
83. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 1896;ii:104-7.
84. Lacassagne A. Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer 1936;27:217-25.
85. Allen E, Doisy EA. An ovarian hormone: Preliminary report on its localization, extraction and partial purification and action in test animals. J Am Med Assoc 1923;81:819-21.
86. Jordan VC. Effect of tamoxifen (IC146.474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976;12:419-24.
87. Jordan VC, Allen KE. Evaluation of the antitumour activity of the non-steroidal antiestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 1980;16:239-51.
88. Gottardis MM, Jordan VC. The antitumor actions of keoxifene (raloxifene) and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987;47:4020-4.
89. Jordan VC, Lababidi MK, Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 1991;83:492-6.
90. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985;ii:282.
91. EBCTCG. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998;351:1451-67.
92. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
93. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairen C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879-86.
94. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-34.
95. Jordan VC, Morrow M. Tamoxifene, raloxifene and the prevention of breast cancer. Endocr Rev 1999;20:253-78.
96. Khuri FR, Lippman SM, Spitz MR, Lotan R, Hong WK. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 1997;89:199-211.
97. Stich HF, Rosin MP, Hornby P, Mathew B, Sankaranarayanan R, Nair MK. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 1988;42:195-9.
98. Hong W, Endicott J, Itri LM, Batsakis JG, Bell R. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501-5.
99. Lippman SM, Batsakis JG, Toth BB, Weber KS, Lee JJ, Martin JW. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993;328:15-20.
100. Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 1988;40:93-101.
101. Han J, Jiao L, Lu Y, Sun Z, Gu QM, Scanlon KJ. Evaluation of N-4-(hydroxycarbophenyl)retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent. In Vivo 1990;4:153-60.
102. Chiesa F, Tradati N, Marazza M, Rossi N, Boracchi P, Mariani L. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem Suppl 1993;17F:255-61.
103. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
104. Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993;11:1216-22.
105. Bolla M, Lefur R, Ton Van J, Domenge C, Badet JM, Koskas Y. Prevention of second primary tumours with etretinate in squamous cell carcinoma of oral cavity and oropharynx: Results of a multicentric double-blind randomised study. Eur J Cancer 1994;30A:767-72.
106. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
107. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
108. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;328:1593-6.
109. Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-9.
110. Giardiello FM, Hamilton SR, Krush AJ. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
111. Steinbach G, Lynch PM, Phillips RKS. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
112. Gustin DM, Brenner DE. Chemoprevention of colon cancer: Current status and future prospects. Cancer Metastasis Rev 2002;21:323-48.
113. Fanif R, Qiao L, Shiff S, Rigas B. Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induced cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med 1997;130:576-94.
114. Cheng AL, Lin JK, Hsu MM, Shen TS, Ko JY, Lin JT, et al. Phase I chemoprevention clinical trial of curcumin. Proc Am Soc Clin Oncol 1998;17:558a.
115. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995;87:517-23.
116. Meyskens FL, Emerson SS, Pelot D, Meshkinpour H, Shassetz LR, Einspaar J. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst 1994;85: 732-6.
117. Meyskens FL, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, et al. Effects of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 1990;16:1212-8.
118. Kelley MJ, McCrory DC. Prevention of lung cancer. Summary of published evidence. Chest 2003;123:50S-9S.
119. Heinonen OP, Huttunen JK, Albanes D. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
120. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
121. Goodman GE, Omenn GS, Thornquist MD. The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high-risk populations: Pilot study with cigarette smokers. Cancer Epidemiol Biomarkers Prev 1993;2:389-96.
122. Patrick L. Beta-carotene: The controversy continues. Altern Med Rev 2000; 5:530-45.
123. Cook NR, Lee IM, Manson JE, Buring JE, Hennekens CH. Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). Cancer Causes Control 2000;11:617-26.
124. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: The Women's Health Study. J Natl Cancer Inst 1999;91:2102-6.
125. de Klerk NH, Musk AQ, Ambrosini GL, Eccles JL, Hansen J, Olsen N, et al. Vitamin A and cancer prevention: II. Comparison of the effects of retinol and beta-carotene. Int J Cancer 1998;75:362-7.